JP2019514925A - 心血管状態におけるセマグルチド - Google Patents
心血管状態におけるセマグルチド Download PDFInfo
- Publication number
- JP2019514925A JP2019514925A JP2018556411A JP2018556411A JP2019514925A JP 2019514925 A JP2019514925 A JP 2019514925A JP 2018556411 A JP2018556411 A JP 2018556411A JP 2018556411 A JP2018556411 A JP 2018556411A JP 2019514925 A JP2019514925 A JP 2019514925A
- Authority
- JP
- Japan
- Prior art keywords
- semaglutide
- placebo
- mace
- fatal
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title claims abstract description 127
- 108010060325 semaglutide Proteins 0.000 title claims abstract description 126
- 229950011186 semaglutide Drugs 0.000 title claims abstract description 126
- 230000002526 effect on cardiovascular system Effects 0.000 title description 59
- 238000000034 method Methods 0.000 claims description 95
- 239000000902 placebo Substances 0.000 claims description 74
- 229940068196 placebo Drugs 0.000 claims description 74
- 230000034994 death Effects 0.000 claims description 49
- 231100000517 death Toxicity 0.000 claims description 49
- 230000000250 revascularization Effects 0.000 claims description 48
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 46
- 206010019280 Heart failures Diseases 0.000 claims description 42
- 230000002829 reductive effect Effects 0.000 claims description 40
- 230000003111 delayed effect Effects 0.000 claims description 34
- 206010002388 Angina unstable Diseases 0.000 claims description 27
- 208000007814 Unstable Angina Diseases 0.000 claims description 27
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 27
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000007211 cardiovascular event Effects 0.000 claims description 16
- 238000011866 long-term treatment Methods 0.000 claims description 10
- 230000001934 delay Effects 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract description 5
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 description 58
- 208000006011 Stroke Diseases 0.000 description 47
- 239000003538 oral antidiabetic agent Substances 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 208000032109 Transient ischaemic attack Diseases 0.000 description 7
- 201000010875 transient cerebral ischemia Diseases 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 230000002641 glycemic effect Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 231100001160 nonlethal Toxicity 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000024924 glomerular filtration Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 4
- 102000016261 Long-Acting Insulin Human genes 0.000 description 4
- 229940100066 Long-acting insulin Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 206010052337 Diastolic dysfunction Diseases 0.000 description 3
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 3
- 102000005561 Human Isophane Insulin Human genes 0.000 description 3
- 108010084048 Human Isophane Insulin Proteins 0.000 description 3
- 108010092217 Long-Acting Insulin Proteins 0.000 description 3
- 206010027525 Microalbuminuria Diseases 0.000 description 3
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000002586 coronary angiography Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 3
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- -1 metformin Chemical compound 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012633 nuclear imaging Methods 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010057573 Chronic hepatic failure Diseases 0.000 description 2
- 208000010334 End Stage Liver Disease Diseases 0.000 description 2
- 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000011444 chronic liver failure Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000011863 diuretic therapy Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 206010013974 Dyspnoea paroxysmal nocturnal Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 101500028773 Homo sapiens Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 206010073149 Multiple endocrine neoplasia Type 2 Diseases 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229940127208 glucose-lowering drug Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 108010071377 human long-acting insulin Proteins 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明に従ってセマグルチドを投与される対象は、成人等のヒトであり得る。一部の実施形態では、前記対象は成人である。
a)過去の心筋梗塞、
b)過去の脳卒中又は一過性虚血発作(TIA)、
c)過去の冠血行再建、頸動脈血行再建、又は末梢動脈血行再建、
d)冠状動脈、頸動脈、又は下肢動脈の血管造影又は画像化での>50%狭窄、
e)症候性の冠動脈性心疾患の既往歴(例えば、正の運動負荷試験又は任意の心臓画像化又はECG変化を伴う不安定狭心症によって記録されている)、
f)無症候の心臓虚血(例えば、正の核画像化試験、又は運動試験、又は負荷エコー又は任意の心臓画像化によって記録されている)、
g)ニューヨーク心臓協会(NYHA)クラスII〜IIIの心不全、及び
h)慢性的な腎機能障害(例えば、推算糸球体濾過量(eGFR)<MDRD当たり60mL/分/1.73m2によって記録されている(スクリーニング前に))
からなる群から選択される少なくとも1つの基準を満たす場合に存在し得る。
i)持続性の微量アルブミン尿(例えば、30〜299mg/g)又はタンパク尿、
j)高血圧及びECG又は画像化による左心室肥大、
k)左心室収縮又は拡張機能不全(例えば、画像化による)、並びに
l)足関節/上腕血圧比<0.9
からなる群から選択される少なくとも1つの基準を満たす場合に存在し得る。
セマグルチドは、GLP-1受容体アゴニストであるN6.26-{18-[N-(17-カルボキシ-ヘプタデカノイル)-L-γ-グルタミル]-10-オキソ-3,6,12,15-テトラオキサ-9,18-ジアザオクタデカノイル}-[8-(2-アミノ-2-プロパン酸),34-L-アルギニン]ヒトグルカゴン様ペプチド1(7-37)であり、その構造を化学式(I)で示す。セマグルチドはまた、N-イプシロン26-[2-(2-{2-[2-(2-{2-[(S)-4-カルボキシ-4-(17-カルボキシヘプタデカノイルアミノ)ブチリルアミノ]エトキシ}エトキシ)アセチルアミノ]エトキシ}エトキシ)アセチル][Aib8,Arg34]GLP-1-(7-37)と呼ぶこともできる。セマグルチドは、WO2006/097537の実施例4において記載されているように調製することができる。
セマグルチドは、医薬組成物の形態で投与することができる。医薬組成物は、0.1mg/mlから100mg/mlの濃度でセマグルチドを含み得る。一部の実施形態では、医薬組成物は、0.01〜50mg、又は0.01〜20mg、又は0.01〜10mg/mlのセマグルチドを含む。一部の実施形態では、医薬組成物は、0.1〜20mg/mlのセマグルチドを含む。
セマグルチドは、治療上効果的な量で、例えば、2型糖尿病を治療するために治療上効果的な量で投与することができる。治療上効果的な量のセマグルチドは、医師によって評価され得る。セマグルチドの投与量は、0.01から10mgの範囲であり得る。
本発明の非限定的な実施形態には、以下のものが含まれる。
MACE:主要心血管イベント
HbA1c:グリコシル化されたヘモグロビン
GLP-1:グルカゴン様ペプチド-1
BMI:ボディマスインデックス
N:対象の数
CV:心血管
OAD:経口糖尿病治療薬
TIA:一過性虚血発作
CI:信頼区間
CKD-EPI:慢性腎臓病疫学共同研究
MDRD:腎臓病における食事改善
MI:心筋梗塞。
UAP:不安定狭心症。
長期の、ランダム化された、二重盲式の、プラセボ対照の、4群からなる並行群の、多施設の、多国籍の、安全性及び有効性試験を行って、2型糖尿病を有する3297人のヒト対象における、セマグルチドを用いる心血管の及び他の長期の結果を評価した。対象の組み入れ及び除外の基準は、Table 2(表3)に記載する通りであった。
a)過去の心筋梗塞、
b)過去の脳卒中又は一過性虚血発作、
c)過去の冠血行再建、頸動脈血行再建、又は末梢動脈血行再建、
d)冠状動脈、頸動脈、又は下肢動脈の血管造影又は画像化での>50%狭窄、
e)症候性の冠動脈性心疾患の既往歴(例えば、正の運動負荷試験又は任意の心臓画像化又はECG変化を伴う不安定狭心症によって記録されている)、
f)無症候の心臓虚血(例えば、正の核画像化試験又は運動試験又は負荷エコー又は任意の心臓画像化によって記録されている)、
g)ニューヨーク心臓協会(NYHA)クラスII〜IIIの心不全、及び
h)慢性的な腎機能障害(推算糸球体濾過量(eGFR)<MDRD当たり60mL/分/1.73m2によって記録されている(スクリーニング前に))。
i)持続性の微量アルブミン尿(30〜299mg/g)又はタンパク尿、
j)ECG又は画像化による高血圧及び左心室肥大、
k)画像化による左心室収縮又は拡張機能不全、及び
l)足関節/上腕血圧比<0.9。
Claims (14)
- 治療上効果的な量のセマグルチドを、それを必要とする対象に投与する工程を含む、2型糖尿病を治療する方法であって、前記対象が、心血管疾患の臨床的エビデンス及び/又は心血管疾患の準臨床的エビデンスを有し、前記方法が、主要心血管イベント(MACE)を遅延又は低減させる、方法。
- 非致死性のMI、非致死性の脳卒中、血行再建、又は不安定狭心症のための入院を遅延又は低減させる、請求項1に記載の方法。
- セマグルチドが、約1〜20mg/mlのセマグルチドを含み、7.0〜9.0の範囲のpHを有する医薬組成物の形態で投与される、請求項1又は2に記載の方法。
- セマグルチドの投与量が、0.1から5.0mgの範囲である、請求項1から3のいずれか一項に記載の方法。
- セマグルチドが、週に1回、0.5又は1.0mgの量で投与される、請求項1から4のいずれか一項に記載の方法。
- 前記MACEが、CV死、非致死性のMI、非致死性の脳卒中、血行再建、心不全のための入院、及び不安定狭心症のための入院からなる群から選択され、MACEが、プラセボと比較して約20%から約35%低減又は遅延され、例えばプラセボと比較して約27%低減される、請求項1から5のいずれか一項に記載の方法。
- 前記MACEが、CV死、非致死性のMI、及び非致死性の脳卒中からなる群から選択され、前記MACEが、プラセボと比較して約20%から約30%低減する、例えばプラセボと比較して約26%低減する、請求項1から6のいずれか一項に記載の方法。
- 前記MACEが、非致死性のMIであり、前記非致死性のMIが、(i)プラセボと比較して約15%から約35%、又は(ii)プラセボと比較して約26%低減又は遅延される、請求項1から7のいずれか一項に記載の方法。
- 前記MACEが、非致死性の脳卒中であり、前記非致死性の脳卒中が、(i)プラセボと比較して約30%から約50%、又は(ii)プラセボと比較して約39%低減又は遅延される、請求項1から8のいずれか一項に記載の方法。
- 前記MACEが血行再建であり、前記血行再建が、(i)プラセボと比較して約30%から約50%、又は(ii)プラセボと比較して約38%低減又は遅延される、請求項1から9のいずれか一項に記載の方法。
- 前記MACEが、不安定狭心症のための入院であり、前記不安定狭心症のための入院が、(i)プラセボと比較して約10%から約30%、又は(ii)プラセボと比較して約18%低減又は遅延される、請求項1から10のいずれか一項に記載の方法。
- 前記MACEが、セマグルチドの投与を開始した後の最初のMACEである、請求項1から11のいずれか一項に記載の方法。
- 前記対象が、(i)30kg/m2以下のBMIを有し、且つ/又は(ii)男性である、請求項1から12のいずれか一項に記載の方法。
- 前記セマグルチドの投与が、セマグルチドが少なくとも18ヶ月、例えば少なくとも30ヶ月にわたり投与される長期治療であり、前記方法が血行再建を低減又は遅延させる、請求項1から13のいずれか一項に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16167458.5 | 2016-04-28 | ||
EP16167458 | 2016-04-28 | ||
EP16188262.6 | 2016-09-12 | ||
EP16188262 | 2016-09-12 | ||
PCT/EP2017/060160 WO2017186896A1 (en) | 2016-04-28 | 2017-04-28 | Semaglutide in cardiovascular conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019514925A true JP2019514925A (ja) | 2019-06-06 |
JP2019514925A5 JP2019514925A5 (ja) | 2020-06-18 |
JP7221694B2 JP7221694B2 (ja) | 2023-02-14 |
Family
ID=58668875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018556411A Active JP7221694B2 (ja) | 2016-04-28 | 2017-04-28 | 心血管状態におけるセマグルチド |
Country Status (22)
Country | Link |
---|---|
US (1) | US20190134162A1 (ja) |
EP (1) | EP3448416B1 (ja) |
JP (1) | JP7221694B2 (ja) |
KR (2) | KR20180135012A (ja) |
CN (1) | CN109069589B (ja) |
AU (1) | AU2017256774A1 (ja) |
BR (1) | BR112018072020A2 (ja) |
CA (1) | CA3022535A1 (ja) |
CL (1) | CL2018003045A1 (ja) |
DK (1) | DK3448416T3 (ja) |
ES (1) | ES2928007T3 (ja) |
HR (1) | HRP20221150T1 (ja) |
HU (1) | HUE060040T2 (ja) |
IL (1) | IL262390B1 (ja) |
MA (1) | MA44762A (ja) |
MX (1) | MX2018012700A (ja) |
PH (1) | PH12018502274A1 (ja) |
PL (1) | PL3448416T3 (ja) |
RS (1) | RS63630B1 (ja) |
RU (1) | RU2768283C2 (ja) |
SI (1) | SI3448416T1 (ja) |
WO (1) | WO2017186896A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180135012A (ko) | 2016-04-28 | 2018-12-19 | 노보 노르디스크 에이/에스 | 심혈관 병태에서의 세마글루타이드 |
AU2018321157B2 (en) | 2017-08-24 | 2024-03-28 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
PL3870213T3 (pl) * | 2018-10-26 | 2023-11-20 | Novo Nordisk A/S | Stabilne kompozycje semaglutydu i ich zastosowania |
EP3897582A1 (en) | 2018-12-21 | 2021-10-27 | Novo Nordisk A/S | Process of spray drying of glp-1 peptide |
IL294521A (en) * | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
CN114699510A (zh) * | 2021-12-29 | 2022-07-05 | 浙江湃肽生物有限公司 | 一种司美格鲁肽微针阵列及其制备方法 |
WO2023238017A1 (en) * | 2022-06-08 | 2023-12-14 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008533105A (ja) * | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | アシル化glp−1化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003084563A1 (en) * | 2002-04-04 | 2003-10-16 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
CA2797310C (en) * | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
SI3326620T1 (sl) * | 2010-12-16 | 2020-07-31 | Novo Nordisk A/S | Trdne sestave, ki vsebujejo agonist GLP-1 in sol N-(8-(2-hidroksibenzoil)amino)kaprilne kisline |
US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
JP6126097B2 (ja) * | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー/エス | Glp−1誘導体 |
JP6602760B2 (ja) * | 2013-11-15 | 2019-11-06 | ノヴォ ノルディスク アー/エス | 選択的なpyy化合物及びその使用 |
KR20180135012A (ko) | 2016-04-28 | 2018-12-19 | 노보 노르디스크 에이/에스 | 심혈관 병태에서의 세마글루타이드 |
-
2017
- 2017-04-28 KR KR1020187033310A patent/KR20180135012A/ko active Application Filing
- 2017-04-28 WO PCT/EP2017/060160 patent/WO2017186896A1/en active Application Filing
- 2017-04-28 CN CN201780026303.2A patent/CN109069589B/zh active Active
- 2017-04-28 HU HUE17721109A patent/HUE060040T2/hu unknown
- 2017-04-28 BR BR112018072020-8A patent/BR112018072020A2/pt unknown
- 2017-04-28 SI SI201731219T patent/SI3448416T1/sl unknown
- 2017-04-28 RU RU2018140900A patent/RU2768283C2/ru active
- 2017-04-28 PL PL17721109.1T patent/PL3448416T3/pl unknown
- 2017-04-28 CA CA3022535A patent/CA3022535A1/en active Pending
- 2017-04-28 EP EP17721109.1A patent/EP3448416B1/en active Active
- 2017-04-28 MX MX2018012700A patent/MX2018012700A/es unknown
- 2017-04-28 AU AU2017256774A patent/AU2017256774A1/en active Pending
- 2017-04-28 JP JP2018556411A patent/JP7221694B2/ja active Active
- 2017-04-28 US US16/097,032 patent/US20190134162A1/en active Pending
- 2017-04-28 ES ES17721109T patent/ES2928007T3/es active Active
- 2017-04-28 KR KR1020227036550A patent/KR20220147712A/ko not_active Application Discontinuation
- 2017-04-28 MA MA044762A patent/MA44762A/fr unknown
- 2017-04-28 HR HRP20221150TT patent/HRP20221150T1/hr unknown
- 2017-04-28 RS RS20220901A patent/RS63630B1/sr unknown
- 2017-04-28 DK DK17721109.1T patent/DK3448416T3/da active
-
2018
- 2018-10-15 IL IL262390A patent/IL262390B1/en unknown
- 2018-10-25 PH PH12018502274A patent/PH12018502274A1/en unknown
- 2018-10-25 CL CL2018003045A patent/CL2018003045A1/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008533105A (ja) * | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | アシル化glp−1化合物 |
Non-Patent Citations (5)
Title |
---|
EXP DIAB RES., 2011, VOL.2011, ARTICLE.215764(P.1-10), JPN6022007814, ISSN: 0004720105 * |
THE LACCET DIABETES & ENDOCRINOLOGY, vol. 3,9, JPN6021006953, 11 August 2015 (2015-08-11), pages 667 - 669, ISSN: 0004720106 * |
循環器内科, 2012, VOL.71 NO.5, P.470-476, JPN6021006947, ISSN: 0004720102 * |
日本臨床, 2011, VOL.69 NO.5, P.836-841, JPN6021006949, ISSN: 0004720103 * |
糖尿病, 2012, VOL.55, NO.SUPPLEMENT 1, P.S-135 (I-P-177), JPN6021006951, ISSN: 0004720104 * |
Also Published As
Publication number | Publication date |
---|---|
PH12018502274A1 (en) | 2019-09-09 |
CL2018003045A1 (es) | 2018-12-14 |
KR20180135012A (ko) | 2018-12-19 |
HUE060040T2 (hu) | 2023-01-28 |
CN109069589B (zh) | 2022-09-06 |
JP7221694B2 (ja) | 2023-02-14 |
RU2768283C2 (ru) | 2022-03-23 |
RS63630B1 (sr) | 2022-10-31 |
RU2018140900A3 (ja) | 2020-09-28 |
HRP20221150T1 (hr) | 2022-11-25 |
RU2018140900A (ru) | 2020-05-28 |
PL3448416T3 (pl) | 2022-11-07 |
EP3448416B1 (en) | 2022-08-10 |
MA44762A (fr) | 2019-03-06 |
KR20220147712A (ko) | 2022-11-03 |
US20190134162A1 (en) | 2019-05-09 |
MX2018012700A (es) | 2019-01-30 |
WO2017186896A1 (en) | 2017-11-02 |
CN109069589A (zh) | 2018-12-21 |
DK3448416T3 (da) | 2022-10-03 |
SI3448416T1 (sl) | 2022-10-28 |
BR112018072020A2 (pt) | 2019-02-12 |
CA3022535A1 (en) | 2017-11-02 |
EP3448416A1 (en) | 2019-03-06 |
ES2928007T3 (es) | 2022-11-14 |
IL262390A (en) | 2018-12-31 |
AU2017256774A1 (en) | 2018-11-01 |
IL262390B1 (en) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7221694B2 (ja) | 心血管状態におけるセマグルチド | |
AU2024201937A1 (en) | Liraglutide in cardiovascular conditions | |
US20220160840A1 (en) | Insulin degludec in cardiovascular conditions | |
US11673933B2 (en) | Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications | |
WO2017149105A1 (en) | Liraglutide in renal conditions | |
Cases | Glucagon-like peptide 1 (GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist | |
WO2017149109A1 (en) | Liraglutide in diabetic foot ulcer | |
Wiernek et al. | Effect of Non–Insulin-Based Glucose-Lowering Therapies on Cardiovascular Outcomes in Patients With Type 2 Diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200428 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210527 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220307 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220907 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230202 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7221694 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |